Drug intelligence / Profile preview

Pekarin

Development stage: Preclinical
Lead developer: BlueSky Immunotherapies
Modality: Vaccines & Immunotherapeutics

Overview

**Pekarin** is a preclinical biological vaccine program developed by BlueSky Immunotherapies for prevention of COVID-19 and influenza. Public pipeline listings identify the program and its infectious-disease indications, but do not disclose its antigen composition, vaccine platform, adjuvant, route of administration, or molecular mechanism of action. ([synapse.patsnap.com](https://synapse.patsnap.com/organization/aa2db43961d8d78fb6aa8112033ae1e2))

Other names: Pekarin

Targets

SARS-CoV-2 spikeHA (Hemagglutinin)

Beyond the preview

Go deeper on Pekarin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pekarin.

Explore the full profile